Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells

Authors: Elisabetta Cavalieri, Antonella Rigo, Massimiliano Bonifacio, Alessandra Carcereri de Prati, Emanuele Guardalben, Christian Bergamini, Romana Fato, Giovanni Pizzolo, Hisanori Suzuki, Fabrizio Vinante

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

We previously demonstrated that the plant-derived agent α-bisabolol enters cells via lipid rafts, binds to the pro-apoptotic Bcl-2 family protein BID, and may induce apoptosis. Here we studied the activity of α-bisabolol in acute leukemia cells.

Methods

We tested ex vivo blasts from 42 acute leukemias (14 Philadelphia-negative and 14 Philadelphia-positive B acute lymphoid leukemias, Ph-/Ph+B-ALL; 14 acute myeloid leukemias, AML) for their sensitivity to α-bisabolol in 24-hour dose-response assays. Concentrations and time were chosen based on CD34+, CD33+my and normal peripheral blood cell sensitivity to increasing α-bisabolol concentrations for up to 120 hours.

Results

A clustering analysis of the sensitivity over 24 hours identified three clusters. Cluster 1 (14 ± 5 μM α-bisabolol IC50) included mainly Ph-B-ALL cells. AML cells were split into cluster 2 and 3 (45 ± 7 and 65 ± 5 μM IC50). Ph+B-ALL cells were scattered, but mainly grouped into cluster 2. All leukemias, including 3 imatinib-resistant cases, were eventually responsive, but a subset of B-ALL cells was fairly sensitive to low α-bisabolol concentrations. α-bisabolol acted as a pro-apoptotic agent via a direct damage to mitochondrial integrity, which was responsible for the decrease in NADH-supported state 3 respiration and the disruption of the mitochondrial membrane potential.

Conclusion

Our study provides the first evidence that α-bisabolol is a pro-apoptotic agent for primary human acute leukemia cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cavalieri E, Mariotto S, Fabrizi C, De Prati AC, Gottardo R, Leone S, Berra LV, Lauro GM, Ciampa AR, Suzuki H: α-bisabolol, a non-toxic natural compound, strongly induces apoptosis in glioma cells. Biochem Biophys Res Commun. 2004, 315: 589-594. 10.1016/j.bbrc.2004.01.088.CrossRefPubMed Cavalieri E, Mariotto S, Fabrizi C, De Prati AC, Gottardo R, Leone S, Berra LV, Lauro GM, Ciampa AR, Suzuki H: α-bisabolol, a non-toxic natural compound, strongly induces apoptosis in glioma cells. Biochem Biophys Res Commun. 2004, 315: 589-594. 10.1016/j.bbrc.2004.01.088.CrossRefPubMed
2.
go back to reference Costarelli L, Malavolta M, Giacconi R, Cipriano C, Gasparini N, Tesei S, Pierpaoli S, Orlando F, Suzuki H, Perbellini L, Piacenza F, Emanuelli M, Mocchegiani E: In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. Oncol Res. 2010, 18: 409-418. 10.3727/096504010X12671222663557.CrossRefPubMed Costarelli L, Malavolta M, Giacconi R, Cipriano C, Gasparini N, Tesei S, Pierpaoli S, Orlando F, Suzuki H, Perbellini L, Piacenza F, Emanuelli M, Mocchegiani E: In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. Oncol Res. 2010, 18: 409-418. 10.3727/096504010X12671222663557.CrossRefPubMed
3.
go back to reference Darra E, Abdel-Azeim S, Manara A, Shoji K, Marechal JD, Mariotto S, Cavalieri E, Perbellini L, Pizza C, Perahia D, Crimi M, Suzuki H: Insight into the apoptosis-inducing action of α-bisabolol towards malignant tumor cells: Involvement of lipid rafts and Bid. Arch Biochem Biophys. 2008, 476: 113-123. 10.1016/j.abb.2008.02.004.CrossRefPubMed Darra E, Abdel-Azeim S, Manara A, Shoji K, Marechal JD, Mariotto S, Cavalieri E, Perbellini L, Pizza C, Perahia D, Crimi M, Suzuki H: Insight into the apoptosis-inducing action of α-bisabolol towards malignant tumor cells: Involvement of lipid rafts and Bid. Arch Biochem Biophys. 2008, 476: 113-123. 10.1016/j.abb.2008.02.004.CrossRefPubMed
4.
go back to reference Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005, 106: 1154-1163. 10.1182/blood-2005-01-0178.CrossRefPubMed Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005, 106: 1154-1163. 10.1182/blood-2005-01-0178.CrossRefPubMed
5.
go back to reference Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS: End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007, 109: 1810-1816. 10.1182/blood-2006-08-041152.CrossRefPubMed Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS: End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007, 109: 1810-1816. 10.1182/blood-2006-08-041152.CrossRefPubMed
6.
go back to reference Lancet JE, Giralt S: Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw. 2008, 6: 1017-1025.PubMed Lancet JE, Giralt S: Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw. 2008, 6: 1017-1025.PubMed
7.
go back to reference Kohrt HE, Coutre SE: Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw. 2008, 6: 1003-1016.PubMed Kohrt HE, Coutre SE: Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw. 2008, 6: 1003-1016.PubMed
8.
go back to reference Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108: 2332-2338. 10.1182/blood-2006-02-004580.PubMedCentralCrossRefPubMed Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108: 2332-2338. 10.1182/blood-2006-02-004580.PubMedCentralCrossRefPubMed
9.
go back to reference Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Bradford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood. 2007, 109: 3207-3213. 10.1182/blood-2006-09-046888.CrossRefPubMed Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Bradford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood. 2007, 109: 3207-3213. 10.1182/blood-2006-09-046888.CrossRefPubMed
10.
go back to reference Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, Aprili F, Perona G: Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998, 12: 144-149. 10.1038/sj.leu.2400912.CrossRefPubMed Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, Aprili F, Perona G: Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998, 12: 144-149. 10.1038/sj.leu.2400912.CrossRefPubMed
11.
go back to reference Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006, 107: 473-479. 10.1182/blood-2005-04-1754.CrossRefPubMed Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006, 107: 473-479. 10.1182/blood-2005-04-1754.CrossRefPubMed
12.
go back to reference Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, for the AIEOP-BFM-FCM-MRD-Study Group: Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia. 2009, 23: 528-534. 10.1038/leu.2008.324.CrossRefPubMed Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, for the AIEOP-BFM-FCM-MRD-Study Group: Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia. 2009, 23: 528-534. 10.1038/leu.2008.324.CrossRefPubMed
13.
go back to reference Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G: Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood. 1999, 93: 1715-1723.PubMed Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G: Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood. 1999, 93: 1715-1723.PubMed
14.
go back to reference Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, Cassatella MA: Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. Blood. 1999, 94: 3169-3177.PubMed Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, Cassatella MA: Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. Blood. 1999, 94: 3169-3177.PubMed
15.
go back to reference Gratama JW, Keeney M, Sutherland DR: Enumeration of CD34+ hematopoietic stem and progenitor cells. Current Protocols in Cytometry. Edited by: Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, Tanke HJ, Wheeless LL. 1999, New York: John Wiley & Sons, 6.4.1-22 Gratama JW, Keeney M, Sutherland DR: Enumeration of CD34+ hematopoietic stem and progenitor cells. Current Protocols in Cytometry. Edited by: Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, Tanke HJ, Wheeless LL. 1999, New York: John Wiley & Sons, 6.4.1-22
16.
go back to reference Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed
17.
go back to reference Chretien D, Bénit P, Chol M, Lebon S, Rötig A, Munnich A, Rustin P: Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochem Biophys Res Commun. 2003, 301: 222-224. 10.1016/S0006-291X(02)03016-4.CrossRefPubMed Chretien D, Bénit P, Chol M, Lebon S, Rötig A, Munnich A, Rustin P: Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochem Biophys Res Commun. 2003, 301: 222-224. 10.1016/S0006-291X(02)03016-4.CrossRefPubMed
18.
go back to reference Nougayrède JP, Donnenberg MS: Enteropathogenic Escherichia coli EspF is targeted to mitochondria and is required to initiate the mitochondrial death pathway. Cell Microbiol. 2004, 611: 1097-1111.CrossRef Nougayrède JP, Donnenberg MS: Enteropathogenic Escherichia coli EspF is targeted to mitochondria and is required to initiate the mitochondrial death pathway. Cell Microbiol. 2004, 611: 1097-1111.CrossRef
19.
go back to reference Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M, Pinti M, Cossarizza A: Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc. 2007, 2: 2719-2727. 10.1038/nprot.2007.405.CrossRefPubMed Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M, Pinti M, Cossarizza A: Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc. 2007, 2: 2719-2727. 10.1038/nprot.2007.405.CrossRefPubMed
20.
go back to reference Zinkel S, Gross A, Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death and Differentiation. 2006, 13: 1351-1359. 10.1038/sj.cdd.4401987.CrossRefPubMed Zinkel S, Gross A, Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death and Differentiation. 2006, 13: 1351-1359. 10.1038/sj.cdd.4401987.CrossRefPubMed
21.
go back to reference Cavalieri E, Bergamini C, Mariotto S, Leoni S, Perbellilni L, Darra E, Suzuki H, Fato R, Lenaz G: Involvement of mitochondrial permeability transition pore opening in alpha-bisabolol induced apoptosis. FEBS J. 2009, 276: 3990-4000. 10.1111/j.1742-4658.2009.07108.x.CrossRefPubMed Cavalieri E, Bergamini C, Mariotto S, Leoni S, Perbellilni L, Darra E, Suzuki H, Fato R, Lenaz G: Involvement of mitochondrial permeability transition pore opening in alpha-bisabolol induced apoptosis. FEBS J. 2009, 276: 3990-4000. 10.1111/j.1742-4658.2009.07108.x.CrossRefPubMed
22.
go back to reference Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G: Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis. 2007, 12: 803-813. 10.1007/s10495-007-0720-1.CrossRefPubMed Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G: Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis. 2007, 12: 803-813. 10.1007/s10495-007-0720-1.CrossRefPubMed
23.
go back to reference Métivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G: Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett. 1998, 61: 157-163. 10.1016/S0165-2478(98)00013-3.CrossRefPubMed Métivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G: Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett. 1998, 61: 157-163. 10.1016/S0165-2478(98)00013-3.CrossRefPubMed
24.
go back to reference Bhatia SP, McGinty D, Letizia CS, Api AM: Fragrance Material Review on α-bisabolol. Food Chem Toxicol. 2008, 46 (Suppl 11): S72-S76.CrossRefPubMed Bhatia SP, McGinty D, Letizia CS, Api AM: Fragrance Material Review on α-bisabolol. Food Chem Toxicol. 2008, 46 (Suppl 11): S72-S76.CrossRefPubMed
25.
go back to reference Kamatou GPP, Viljoen AM: A review of the application and pharmacological properties of α-bisabolol and α-bisabolol-rich oils. J Am Oil Chem Soc. 2009, 28: 1-7. Kamatou GPP, Viljoen AM: A review of the application and pharmacological properties of α-bisabolol and α-bisabolol-rich oils. J Am Oil Chem Soc. 2009, 28: 1-7.
26.
go back to reference Stanulla M, Schrappe M: Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009, 46: 52-63. 10.1053/j.seminhematol.2008.09.007.CrossRefPubMed Stanulla M, Schrappe M: Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009, 46: 52-63. 10.1053/j.seminhematol.2008.09.007.CrossRefPubMed
27.
go back to reference Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arkinghaus RB, Huang P: Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008, 22: 1191-1199. 10.1038/leu.2008.74.PubMedCentralCrossRefPubMed Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arkinghaus RB, Huang P: Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008, 22: 1191-1199. 10.1038/leu.2008.74.PubMedCentralCrossRefPubMed
28.
go back to reference Druker BJ: Circumventing resistance to kinase-inhibitor therapy. N Engl J Med. 2006, 354: 2594-2596. 10.1056/NEJMe068073.CrossRefPubMed Druker BJ: Circumventing resistance to kinase-inhibitor therapy. N Engl J Med. 2006, 354: 2594-2596. 10.1056/NEJMe068073.CrossRefPubMed
29.
go back to reference Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med. 2006, 354: 2531-2541. 10.1056/NEJMoa055229.CrossRefPubMed Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med. 2006, 354: 2531-2541. 10.1056/NEJMoa055229.CrossRefPubMed
30.
go back to reference Lugli E, Troiano L, Ferraresi R, Roat E, Prada N, Nasi M, Pinti M, Cooper EL, Cossarizza A: Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry. 2005, 68: 28-35.CrossRefPubMed Lugli E, Troiano L, Ferraresi R, Roat E, Prada N, Nasi M, Pinti M, Cooper EL, Cossarizza A: Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry. 2005, 68: 28-35.CrossRefPubMed
Metadata
Title
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells
Authors
Elisabetta Cavalieri
Antonella Rigo
Massimiliano Bonifacio
Alessandra Carcereri de Prati
Emanuele Guardalben
Christian Bergamini
Romana Fato
Giovanni Pizzolo
Hisanori Suzuki
Fabrizio Vinante
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-45

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.